Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination has become a major part of the strategy to reduce Coronavirus disease 2019 (COVID-19) numbers worldwide. To date, vaccinations based on several mechanisms have been used clinically, although relapse of existent glomerulonephritis presenting as gross hematuria, and occurrence of de novo glomerulonephritis have been reported.
Case presentation
We report the first sibling cases newly diagnosed as immunoglobulin A (IgA) nephropathy after the second dose of SARS-CoV-2 vaccination. 15- and 18-year-old men presented with gross hematuria following the second dose of SARS-CoV-2 vaccine (Pfizer, BNT162b2) received on the same day. Pathological findings of each kidney biopsy specimen were consistent with IgA nephropathy. Gross hematuria in both cases spontaneously recovered within several days.
Conclusions
These cases indicate that SARS-CoV-2 vaccination might trigger de novo IgA nephropathy or stimulate its relapse, and also highlight the necessity of understanding the immunological responses to the novel mRNA vaccines in patients with kidney diseases.
Hinweise
Yuri Uchiyama and Hirotaka Fukasawa have contributed equally to this manuscript as co-first authors
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
CD
cluster of differentiation
COVID-19
coronavirus disease 2019
CRP
C-reactive protein
eGFR
estimated glomerular filtration rate
HCO3-
bicarbonate
IgA
immunoglobulin A
LDL
low-density lipoprotein
mRNA
messenger ribonucleic acid
NAG
N-acetyl-glucosaminidase
PAS
Periodic acid Shiff
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
TLR
toll-like receptor
Background
Coronavirus disease 2019 (COVID-19) pandemic is a public health emergency all over the world and its effective control is expected by the execution of a global vaccination strategy [1]. Recently, several types of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) developed and progressively used worldwide [2‐5].
On the other hand, several studies have reported the appearance of gross hematuria following messenger ribonucleic acid (mRNA)-based SARS-CoV-2 vaccination in patients with glomerulonephritis or in patients developing de novo glomerulonephritis post vaccination, especially those with immunoglobulin A (IgA) nephropathy [6‐14].
Anzeige
In this manuscript, we report the first sibling cases of newly diagnosed IgA nephropathy who developed gross hematuria following the second dose of SARS-CoV-2 vaccination.
Case presentation
Patient 1
A 15-year-old Japanese man with a 6-months history of microscopic hematuria was referred to our hospital due to gross hematuria 1 day after receiving the second dose of SARS-CoV-2 vaccine (Pfizer, BNT162b2). He also had fever and myalgia. He had no prior history of COVID-19 infection, nor gross hematuria after any other infections. He had no family medical history of kidney diseases.
Physical examination on admission revealed body temperature of 37.7 °C, pulse rate of 72 beats/min, blood pressure of 115/64 mmHg and no costovertebral angle tenderness.
Laboratory findings revealed serum creatinine of 0.97 mg/dL, estimated glomerular filtration rate (eGFR) of 92 mL/min/1.73 m2, and urinalysis revealed numerous red blood cells and moderate proteinuria Table 1. There was no morphological abnormality of his kidneys in the imaging of computed tomography scan.
Table 1
Clinical characteristics and laboratory findings on initial presentation
The kidney biopsy was performed 7 days after the onset of gross hematuria. Among 21 glomeruli sampled, there were no globally sclerotic glomeruli. All glomeruli showed diffuse and mild mesangial expansion and hypercellularity, and 1 of which had a cellular crescent formation. There was approximately 10-20% tubulointerstitial fibrosis of the cortex and no arterio- and arteriolosclerosis. Immunofluorescence revealed global mesangial staining of IgG (1+), IgA (2+), IgM (±), C3 (1+), C4 (-) C1q (-) and fibrinogen (±). Ultrastructural examination revealed electron dense deposits in the mesangium and mild podocyte foot process effacement (Fig. 1). Pathological features were consistent with IgA nephropathy and the Oxford MEST-C classification was M1E0S0T0C1 [15]. His gross hematuria spontaneously resolved within 6 days without any treatment, although his microscopic hematuria and proteinuria persisted after that.
Fig. 1
Findings of the kidney biopsy specimens from patient 1. (A) Glomerular mesangial expansion and hypercellularity was observed (arrowheads). A cellular crescent formation was also observed. (PAS staining, × 400). (B) Glomerular mesangial deposits for IgA antisera were observed (immunofluorescence study, × 400). (C) Approximately 10-20% tubulointerstitial fibrosis of the cortex was observed (Azan staining, ×100). (D) Ultrastructural evaluation revealed the electron-dense deposits in the mesangium (arrowheads, transmission electron microscopy, x4000). Abbreviation: IgA, Immunoglobulin A; PAS, Periodic acid Shiff
×
Patient 2
An 18-year-old Japanese man with a 3-years history of microscopic hematuria was referred to our hospital due to gross hematuria 2 days after receiving the second dose of the SARS-CoV-2 vaccine (Pfizer, BNT162b2). In fact, he was the brother of patient 1 and had received the vaccination on the same day. He also had fever and general malaise. He had no prior history of COVID-19 infection, nor gross hematuria after any other infections. He had no family medical history of kidney diseases.
Physical examination on admission revealed body temperature of 38.6 °C, pulse rate of 83 beats/min, blood pressure of 131/76 mmHg and no costovertebral angle tenderness.
Laboratory findings revealed serum creatinine of 0.82 mg/dL, eGFR of 99 mL/min/1.73 m2, and urinalysis revealed numerous red blood cells and mild proteinuria Table 1. There was no morphological abnormality of his kidneys in the imaging of computed tomography scan.
The kidney biopsy was performed 3 months after the onset of gross hematuria. Among 67 glomeruli sampled, there were no globally sclerotic glomeruli. All glomeruli showed diffuse and mild mesangial hypercellularity without crescent formation. There was approximately 10 % tubulointerstitial fibrosis of the cortex and no arterio- and arteriolosclerosis. Immunofluorescence revealed global mesangial staining of IgG (±), IgA (2+), IgM (±), C3 (1+), C4 (-) C1q (±) and Fibrinogen (±). Ultrastructural examination revealed electron dense deposits in the mesangium and mild podocyte foot process effacement (Fig. 2). Pathological features were consistent with IgA nephropathy and the Oxford MEST-C score was M1E0S0T0C0 [15]. His gross hematuria spontaneously resolved within 7 days without any treatment, and his microscopic hematuria and proteinuria also disappeared gradually.
Fig. 2
Findings of the kidney biopsy specimens from patient 2. (A) Glomerular mesangial expansion and hypercellularity was observed (arrowheads). (PAS staining, × 400). (B) Glomerular mesangial deposits for IgA antisera were observed (immunofluorescence study, × 400). (C) Approximately 10% tubulointerstitial fibrosis of the cortex was observed (Azan staining, ×100). (D) Ultrastructural evaluation revealed the electron-dense deposits in the mesangium (arrowheads, transmission electron microscopy, ×4000). Abbreviation: IgA, Immunoglobulin A; PAS, Periodic acid Shiff.
×
Discussion and conclusions
To our best knowledge, this is the first report showing sibling cases that developed gross hematuria and were newly diagnosed as IgA nephropathy following the SARS-CoV-2 vaccination.
Recent reports indicate an association between gross hematuria and the SARS-CoV-2 vaccination in patients with glomerulonephritis, especially those with IgA nephropathy [6‐14]. To date, vaccinations based on several mechanisms have been used clinically, although gross hematuria was only reported after receiving the mRNA vaccines [2‐5]. The BNT162B2 (Pfizer) and the mRNA-1273 (Moderna) vaccines employ a purified mRNA lipid nanoparticle-encapsulated platform. This novel mRNA-based platform induces stronger antigen-specific cluster of differentiation (CD) 4+ and CD 8+ T cell responses [16]. Because the CD 4+ and CD 8+ T cells activated by vaccination produce several proinflammatory cytokines, including interferon-γ and tumor necrosis factor-α, these vaccines might exacerbate immune-mediated glomerular diseases or cause de novo glomerulonephritis including IgA nephropathy [6].
One notable point in the present cases is that microscopic hematuria has already existed before the vaccination. In addition, the chronic histopathologic features such as tubulointerstitial damage indicate the possibility that the immune responses to vaccination exacerbated a pre-existing undiagnosed IgA nephropathy in our cases.
Anzeige
Another notable point is the association between the pathogenesis of IgA nephropathy and Toll-like receptors (TLRs), which are a family of immune receptors whose activation is important for the mucosal immune responses [17]. Increased amounts of abnormally glycosylated IgA1 have been thought to be the first hit in the development of IgA nephropathy [18]. Recently, it was reported that TLR7 recognizes endogenous or exogenous single-strand RNAs and is involved in the production of abnormally glycosylated IgA1 [19]. Taken together, it is possible that the mRNA vaccination causes the production of abnormally glycosylated IgA1 via TLR signaling and is related to the exacerbation of IgA nephropathy, at least partially [20].
In conclusion, we report the first sibling cases of newly diagnosed IgA nephropathy who developed gross hematuria following the second dose of SARS-CoV-2 vaccination. These cases indicate that SARS-CoV-2 vaccination might stimulate the relapse or trigger de novo IgA nephropathy. On the other hand, it remains to be unknown that gross hematuria developed in our patients was caused by chance or due to the genetic related etiology. Further studies are needed to identify how this postvaccination setting can develop and how we should manage these patients with IgA nephropathy.
Acknowledgments
None
Declarations
Ethics approval and consent to participate
Not applicable.
Anzeige
Consent for publication
Written informed consent was obtained from the patients and their parents for the publication of this case report. A copy of the written consent is available for review by the editor of this journal.
Competing interests
The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
